医学
亚临床感染
心肌炎
肺癌
无容量
免疫系统
肺
癌症
免疫学
免疫检查点
肿瘤科
免疫疗法
内科学
作者
Yue Hu,Cuixia Liu,Shaojun Jin,Zihan Yi,Chao Wang,Xiaohong Pan,Huaqiong Huang
标识
DOI:10.1186/s12890-023-02417-4
摘要
Immune checkpoint inhibitors (ICIs) have been widely used in the treatment of cancer. Moreover, immune-related adverse events (irAEs) have become a new clinical challenge. ICI-associated myocarditis is a rare but fatal condition among diverse organ injuries, and early recognition and effective interventions are critical for patients.In this report, we present the case of a healthy 60-year-old male who was diagnosed with lung squamous cell carcinomas following chemotherapy and received ICIs. The patient presented with asymptomatic cardiac biomarker elevation followed by immune-related myocarditis. Fortunately, the patient achieved a good clinical result after receiving high-dose steroids. The treatment with ICIs was discontinued because of recurrent increases in troponin T.ICI-mediated associated myocarditis is an uncommon but potentially life-threatening adverse event. The current data suggest that clinicians need to be cautious about reinitiation in low-grade patients; however, further study of the diagnosis and treatment is necessary.
科研通智能强力驱动
Strongly Powered by AbleSci AI